

Produktinformation



Forschungsprodukte & Biochemikalien
Zellkultur & Verbrauchsmaterial
Diagnostik & molekulare Diagnostik
Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien T. +43(0)1 489 3961-0 F. +43(0)1 489 3961-7 <u>mail@szabo-scandic.com</u> www.szabo-scandic.com

Product Information



KRN 633

Item No. 14871

CAS Registry No.:	286370-15-8	
Formal Name:	N-[2-chloro-4-[(6,7-dimethoxy-4-	
	quinazolinyl)oxy]phenyl]-N'-propyl-urea	
MF:	$C_{20}H_{21}CIN_4O_4$	0 ~ 1
FW:	416.9	o l
Purity:	≥95%	
Stability:	≥2 years at -20°C	
Supplied as:	A crystalline solid	
UV/Vis.:	λ _{max} : 210, 242, 320 nm	 CI H H

Laboratory Procedures

For long term storage, we suggest that KRN 633 be stored as supplied at -20°C. It should be stable for at least two years. KRN 633 is supplied as a crystalline solid. A stock solution may be made by dissolving the KRN 633 in the solvent of choice. KRN 633 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of KRN 633 in these solvents is approximately 0.3 and 10 mg/ml, respectively.

KRN 633 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, KRN 633 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. KRN 633 has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

KRN 633 is an ATP-competitive inhibitor of VEGFR kinase activity (IC₅₀s = 170, 160, and 125 nM for VEGFR1, 2, and 3, respectively).¹ At higher concentrations KRN 633 inhibits PDGFR- α and c-KIT with IC_{50} values of 0.97 and 4.3 μ M, respectively, and is inactive towards a panel of 17 additional kinases.¹ KRN 633 suppresses VEGF-dependent activation of MAPK and cell proliferation and demonstrates antitumor and antiangiogenic activity by inhibiting vessel formation and vascular permeability in human tumor xenograft models.²

References

- 1. Fedorov, O., Marsden, B., Pogacic, V., et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc. Natl. Acad. Sci. USA 104(51), 20523-20528 (2007).
- Nakamura, K., Yamamoto, A., Kamishohara, M., et al. KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth. Mol. Cancer Ther. 3(12), 1639-1649 (2004).

Related Products

SAFETY DATA

For a list of related products please visit: www.caymanchem.com/catalog/14871

Cayman Chemical

Mailing address

1180 E. Ellsworth Road Ann Arbor, MI 48108 USA

Phone (800) 364-9897 (734) 971-3335

Fax (734) 971-3640

E-Mail

WARRANTY AND LIMITATION OF REMEDY

DIAGNOSTIC OR THERAPEUTIC USE.

Cayman Chemical Company makes no warranty or guarantee of any kind, whether written or oral, expressed or implied, including without limitation, any warranty of fitness for a particular purpose, suitability and merchantability, which extends beyond the description of the chemicals hereof. Cayman warrants only to the original customer that the material will meet our specifications at the time of delivery.

This material should be considered hazardous until information to the contrary becomes available. Do not ingest, swallow, or inhale. Do not get in eyes, on skin, or on clothing. Wash thoroughly after handling. This information contains some, but not all, of the information required for the safe and proper use of this material. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARNING: This product is for laboratory research only: not for administration to humans. Not for human or veterinary

ar the time of delivery. Cayman will carry out its delivery obligations with due care and skill. Thus, in no event will Cayman have **any obligation or liability**, whether in tort (including negligence) or in contract, for any direct, indirect, indirect incidental or consequential damages, even if Cayman is informed about their possible existence. This limitation of liability does not apply in the case of intentional acts or negligence of Cayman, its directors or its employees. Buyer's **exclusive remedy** and Cayman's sole liability hereunder shall be limited to a <u>refund</u> of the purchase price, or at Cayman's option, the <u>replacement</u>, at no cost to Buyer, of all material that

Buyer's exclusive remedy and Laymans sole hability neterinder shall be infinited to a terminal of the particular process of an experimental strength of the particular process of

custserv@caymanchem.com Web

www.cavmanchem.com